In order to ensure that the cost of the end public health clinical products is kept low, it is imperative that the cost of clinical trials is kept low without compromising on the quality of the clinical research in developing the products.

This would be possible with the increased participation of premier public and private sector institutions across the country to conduct international quality clinical research to develop vaccines, diagnostics and drugs that are safe, effective and affordable.

In this endeavor, CDSA will strive to maintain a lean team of clinical, medical, product development, regulatory and biometric experts liaising with a network of collaborating partners and institutions to provide customized support.